Physician profile
Gincy Samuel
NPI 1821298399
$82,802.77
in general payments reported to CMS, 2019-2025
73 companies · $3,077 in 2025
The $3,077 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,869 · 2020: $29K · 2021: $12K · 2022: $16K · 2023: $12K · 2024: $9,293 · 2025: $3,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $7,812 · Honoraria: $1,400 · Travel and Lodging: $38.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,925.00 |
| Food and Beverage | $7,812.16 |
| Honoraria | $1,400.00 |
| Travel and Lodging | $38.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $33,142.72 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Abbvie INC. | $22,122.49 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Allergan, INC. | $10,485.12 | 2019-2021 | |
| Biogen, INC. | $2,259.48 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Lundbeck LLC | $1,965.21 | 2022-2025 | Vyepti, Rexulti |
| Ucb, INC. | $1,041.78 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Genentech USA, INC. | $971.86 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $799.44 | 2020-2025 | Ajovy |
| Novartis Pharmaceuticals Corporation | $746.95 | 2019-2025 | |
| Argenx US, INC. | $735.68 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Sunovion Pharmaceuticals INC. | $590.81 | 2019-2022 | |
| Amgen INC. | $588.72 | 2019-2025 | Uplizna |
| Merz Pharmaceuticals, LLC | $578.02 | 2021-2024 | Xeomin |
| Alexion Pharmaceuticals, INC. | $456.72 | 2019-2024 | Ultomiris, Soliris |
| Upsher-Smith Laboratories LLC | $425.40 | 2019-2023 |
Show all 70 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,600,758.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gincy Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.